GlassScriptPhysician profile
Jon Evan Stevenson
NPI 1649255241
$5,605.47
in general payments reported to CMS, 2019-2025
44 companies · $659 in 2025
The $659 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,111 · 2020: $912 · 2021: $1,147 · 2022: $560 · 2023: $784 · 2024: $432 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781 · Debt Forgiveness: $93.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.08 |
| Debt Forgiveness | $93.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $496.50 | 2020-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $392.74 | 2019-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $348.91 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $320.21 | 2019-2022 | |
| Pfizer INC. | $305.78 | 2019-2025 | |
| Abbott Laboratories | $285.42 | 2019-2025 | Cardiomems, Aveir |
| Philips North America LLC | $279.12 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $271.82 | 2019-2023 | |
| Heartflow, INC. | $253.75 | 2023-2025 | Ffrct |
| Astellas Pharma US INC | $220.46 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $206.42 | 2022-2025 | Assure Wcd |
| Atricure, INC. | $183.62 | 2023-2024 | |
| Shockwave Medical, INC | $169.49 | 2021 | |
| Baxter Healthcare | $148.08 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Amgen INC. | $136.40 | 2019-2025 | Repatha, Repatha |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.